



10031774
JG03 Rec'd PTO 23 JAN 2002

FORM PTO-1390 (REV. 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER H0664/7003
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/031774
INTERNATIONAL APPLICATION NO. PCT/GB00/02652	INTERNATIONAL FILING DATE 10 July 2000 (10.07.00)	PRIORITY DATE CLAIMED 23 July 1999 (23.07.99)	
TITLE OF INVENTION IMMUNOSUPPRESSION BY CELL SURFACE EXPRESSION OF RECOMBINANT CD154			
APPLICANT(S) FOR DO/EO/US HEATH, Andrew, William			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the earliest claimed priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(C)(5)). 			
Items 11. To 16. Below concern document(s) or information included:			
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> Copy of PCT Published Application w/ International Search Report Copy of International Search Report (copies of references attached to the Information Disclosure Statement) Copy of Written Opinion Copy of International Preliminary Examination Report w/ Amendments Express Mail Label No. EL819462338US Date Mailed: January 23, 2002 IFD/JRV 			

10031774 00000000

JG13 Rec'd PCT/PTO 23 JAN 2002

U.S. APPLICATION NO. <u>107031774</u>		INTERNATIONAL APPLICATION PCT/GB00/02652	ATTORNEY'S DOCKET NUMBER H0664/7003
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but but international search fee paid to USPTO (37 CFR 1.445(a)(2)). paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) But all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = 860.00			CALCULATIONS <small>PTO USE ONLY</small>
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$860.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	20-20=	0	X \$18.00
Independent Claims	5-3 =	2	X \$80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable) 0			+\$270.00
TOTAL OF ABOVE CALCULATIONS			= \$1020.00
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			\$
SUBTOTAL			= \$1020.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
TOTAL NATIONAL FEE			= \$1020.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate coversheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$
TOTAL FEES ENCLOSED			= \$1020.00
			Amount to be: \$
			refunded
			charged \$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1020.00</u> To cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ In the amount of \$ _____ To cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:		 SIGNATURE John R. Van Amsterdam NAME	
WOLF, GREENFIELD & SACKS, P.C. 600 Atlantic Avenue Boston, Massachusetts 02210 Tel: (617) 720-3500		40,212 REGISTRATION NO.	
CUSTOMER NUMBER		 23628	

Express Mail Number: EL 819462338 US
Date of Deposit: January 23, 2002

ATTORNEY'S DOCKET NO. H0664/7003 (JRV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :
Int'l Application No. : PCT/GB00/02652
Int'l Filing Date : 10 July 2000 (10.07.00)
Priority Date : 23 July 1999 (23.07.99)
Title : IMMUNOSUPPRESSION BY CELL SURFACE
EXPRESSION OF RECOMBINANT CD154

Commissioner for Patents
Box PCT
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the United States national phase application of the above-identified PCT international application as follows.

In the Specification

Please add the following section as the first section of the specification following the title.

Related Applications

This application is a national stage filing under 35 U.S.C. § 371 of PCT International application PCT/GB00/02652, filed July 10, 2000, which was published under PCT Article 21(2) in English.

In the Claims

Please amend the claims, which previously were amended under PCT Article 34, as follows. Applicants have included herewith pages showing markups of the claims with insertions and deletions indicated by underlining and bracketing, respectively.

1. (amended) A method for the manufacture of a tissue composition for use in tissue engineering, comprising

transfecting a cell, which does not naturally express CD154, with a nucleic acid molecule encoding CD154.

2.(amended) The method of claim 1, wherein said cell is transfected with genomic DNA.

3.(amended) The method of claim 1, wherein said cell is transfected with cDNA.

4.(amended) The method of claim 1, wherein said cell is of mammalian origin.

5.(amended) The method of claim 4, wherein said cell is of human origin.

6.(amended) The method of claim 1, wherein said cell is selected from the group consisting of fibroblasts; keratinocytes; osteoblasts; chondrocytes; neurones; myocytes; hepatocytes; splenocytes; and pancreatic β cells.

7.(amended) The method of claim 1, wherein the tissue composition is used in the manufacture of a medicament for use in therapeutic tissue engineering.

8.(amended) The method of claim 1, wherein the tissue composition is used in the manufacture of a medicament for use in cosmetic tissue engineering.

9.(amended) A method for the manufacture of a medicament for use in tissue engineering, comprising

expressing CD154 in a cell or tissue from a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154.

10.(amended) The method of claim 9, wherein said vector comprises a cell/tissue specific promoter sequence.

11.(amended) The method of claim 10, wherein said promoter is cell/tissue specific for at least one tissue type selected from the group consisting of neuronal; smooth muscle; striated

528131.1

muscle; cardiac muscle; bone; cartilage; liver; kidney; respiratory epithelium; endothelium; haematopoietic cells; spleen; pancreas; skin; stomach; intestine; oesophagus; and blood vessels.

12.(amended) An *in vitro* method to transfect a selected cell/tissue wherein said cell/tissue does not naturally express CD154, comprising:

- i) incubating cells/tissues under conditions conducive to the introduction and maintenance of a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154;
- ii) exposing said cells/tissues to an agent at a concentration sufficient such that at least those cells/tissues including said vector are selected for and optionally,
- iii) culturing said cells/tissues containing said vector; and, optionally further still,
- iv) storing said cultured cells/tissues.

14.(amended) A method according to claim 13 wherein said mammalian cell/tissue is of human origin.

15.(amended) A method according to claim 12 wherein said transfection is transient.

16.(amended) An organ comprising at least one cell, wherein said cell does not naturally express CD154, which cell has been transfected with a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154.

18.(amended) A therapeutic vehicle comprising a cell transfected according to claim 1.

19.(amended) A therapeutic vehicle according to claim 18 wherein said therapeutic vehicle is selected from the group consisting of prostheses; implants; matrices; stents; gauzes; bandages; plasters; biodegradable matrices; and polymeric films.

20.(amended) A cosmetic vehicle comprising a cell transfected according to claim 1.

Remarks

Applicants have amended the specification to provide priority application information and information regarding the publication in English under PCT Article 21(2) of the PCT application of which the above-identified application is a U.S. national stage application. The claims were amended to remove multiple dependencies and to make the claims consistent with United States claim format convention. No new matter has been added.

Respectfully submitted,



John R. Van Amsterdam

Reg. No. 40,212

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210

Tel: (617) 720-3500

Attorney's Docket No. H0664/7003

Dated: January 23, 2002

XNDD

Added Section:**Related Applications**

This application is a national stage filing under 35 U.S.C. § 371 of PCT International application PCT/GB00/02652, filed July 10, 2000, which was published under PCT Article 21(2) in English.

Amended Claims:

1. (amended) A method for the manufacture of a tissue composition for use in tissue engineering, comprising [Use of]

transfecting a cell, which does not naturally express CD154, [wherein said cell is transfected] with a nucleic acid molecule [DNA] encoding CD154[, for the manufacture of a tissue composition for use in tissue engineering].

2.(amended) The method of claim 1, [Use according to Claim 1] wherein said cell is transfected with genomic DNA.

3.(amended) The method of claim 1, [Use according to Claim 1] wherein said cell is transfected with cDNA.

4.(amended) The method of claim 1, [Use according to any of claims 1-3] wherein said cell is of mammalian origin.

5.(amended) The method of claim 4, [Use according to Claim 4] wherein said cell is of human origin.

6.(amended) The method of claim 1, [Use according to any of claims 1-5] wherein said cell is selected from the group consisting of [following cell types:] fibroblasts; keratinocytes; osteoblasts; chondrocytes; neurones; myocytes; hepatocytes; splenocytes; and pancreatic β cells.

7.(amended) The method of claim 1, wherein the tissue composition is [Use of a cell according to any of claims 1-6 for] used in the manufacture of a medicament for use in therapeutic tissue engineering.

8.(amended) The method of claim 1, wherein the tissue composition is [Use of a cell according to any of claims 1-6 for] used in the manufacture of a medicament for use in cosmetic tissue engineering.

9.(amended) A method for the manufacture of a medicament for use in tissue engineering, comprising [Use of]
expressing CD154 in a cell or tissue from a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154[, for the manufacture of a medicament for use in tissue engineering].

10.(amended) The method of claim 9, [Use of a vector according to claim 9] wherein said vector comprises a cell/tissue specific promoter sequence.

11.(amended) The method of claim 10, [Use of a vector according to claim 10] wherein said promoter is cell/tissue specific for [one of the following] at least one tissue type[s:] selected from the group consisting of neuronal; smooth muscle; striated muscle; cardiac muscle; bone; cartilage; liver; kidney; respiratory epithelium; endothelium; haematopoietic cells; spleen; pancreas; skin; stomach; intestine; oesophagus; and blood vessels.

12.(amended) An *in vitro* method to transfect a selected cell/tissue wherein said cell/tissue does not naturally express CD154, comprising:

- v) incubating cells/tissues under conditions conducive to the introduction and maintenance of a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154 [according to any of claims 9-11];
- vi) exposing said cells/tissues to an agent at a concentration sufficient such that at least those cells/tissues including said vector are selected for and optionally,

- vii) culturing said cells/tissues containing said vector; and, optionally further still,
- viii) storing said [cell] cultured cells/tissues [prior to use].

14.(amended) A method according to claim [12 or] 13 wherein said mammalian cell/tissue is of human origin.

15.(amended) A method according to [any of] claim[s] 12[-14] wherein said transfection is transient.

16.(amended) An organ comprising at least one cell, wherein said cell does not naturally express CD154, which cell has been transfected with a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154 [according to any of Claims 9-11].

18.(amended) A therapeutic vehicle comprising a cell transfected according to [any of] claim[s] 1[-8].

19.(amended) A therapeutic vehicle according to claim 18 wherein said therapeutic vehicle is selected from the group consisting of: a prosthesis] prostheses; implants; matrices [matrix]; stents; gauzes; bandages; plasters; biodegradable matrices [matrix]; and polymeric films.

20.(amended) A cosmetic vehicle comprising a cell transfected according to [any of] claim[s] 1[-8].

CD154 LIGAND, AND RECOMBINANT CELLS EXPRESSING IT

The invention herein described relates to cells and/or tissues and/or organs which do not naturally express the cell surface receptor CD40 ligand, CD154, for use, particularly but not exclusively, in therapeutic and cosmetic tissue engineering and/or organ transplantation; compositions comprising said cells and/or tissues; organs comprising said cells/tissues; and methods of therapy and/or cosmetic surgery using said cells and/or tissues and/or organs.

10 Tissue engineering is an emerging science which has implications with respect to many areas of clinical and cosmetic surgery. More particularly, tissue engineering relates to the replacement and/or restoration and/or repair of damaged and/or diseased tissues to return the tissue and/or organ to a functional state. For example, and not by way of limitation, tissue engineering is useful in the provision of skin
15 grafts to repair wounds occurring as a consequence of: contusions, or burns, or failure of tissue to heal due to venous or diabetic ulcers. Further, tissue engineering is also practised during: replacement of joints through degenerative diseases such as arthritis; replacement of coronary arteries due to damage as a consequence of various environmental causes (e.g. smoking, diet) and/or congenital heart disease including
20 replacement of arterial/heart valve; repair of gastric ulcers; replacement bone tissue resulting from diseases such as osteoporosis; replacement muscle and nerves as a consequence of neuromuscular disease or damage through injury.

In addition, organ transplantation has for many years been an established surgical
25 technique to replace damaged and/or diseased organs. The replacement of heart, lung, kidney, liver, bone marrow, and double organ transplantation of, for example and not by way of limitation, heart and lung, are relatively common procedures.

However, in both tissue engineering and organ transplantation a major obstacle to the
30 successful establishment of a tissue graft or organ transplantation is the host's rejection of the donated tissue or organ.

With respect to tissue engineering and organ transplantation, surgeons currently have three types of graft/organ:

- 5 i. an autograft in which a piece of tissue is removed from one area of a patient's body and placed in another location;
- ii. an allograft, in which a section of tissue from one human, for example a cadaver, is grafted onto another human; and
- 10 iii. a xenograft, where tissue is harvested from another species, for example a pig, and placed over the wound area.

Autografts can be problematic due to the availability of suitable tissue and the added trauma to the patient following the removal of the tissue from another part of the
15 body to the wound area. Allografts can be problematic due to the immunological reactivity of the host and/or the availability of donor tissue/organ. Xenografts are even more problematic due to the severe immunological reactivity of the host and the psychological problems relating to the implantation or grafting of tissue/organ from a non- human species onto or into a human body.

20

The body has developed many defences against invasion of foreign organisms. These humoral and cellular defence mechanisms are also directed against foreign antigens expressed by various tissues/organs used in tissue engineering and/or organ transplantation.

25

A general term to cover a number of distinct cell types intimately involved in both a humoral and cellular defence mechanism is white blood cells. Each white blood cell type has a separate role to play in a hosts immune system. Monocytes are large white blood cells that differentiate into macrophages. The macrophages are found
30 throughout the body in various types. For example specialised macrophages include alveolar macrophages in the lungs, mesangial phagocytes in the kidneys, microglial cells in the brain, and Kupffer cells in the liver. Macrophages have many roles and

these include, by example and not by way of limitation, ingestion of infectious agents, antigen presentation to T-lymphocytes and the secretion of agents involved in regulating the immune system (i.e. interleukin-1, complement proteins).

- 5 A pivotal cell-cell interaction between the many cell types of the immune system is between T- lymphocytes (T- cells) and B- lymphocytes (B- cells). T – cells recognise polypeptide antigens presented as peptides via self molecules referred to as the major histocompatibility complex (MHC) on antigen presenting cells such as macrophages. T-cells are divided into cytotoxic T- cells (CTL's) and T- helper cells.
- 10 The latter class of T-cell are able to stimulate B- cell proliferation and mediate immunoglobulin isotype switching to produce antibody isotypes (IgG, IgA, IgD, IgM, IgE) to specific peptide antigens.

- The regulation of biochemical and physiological responses to foreign antigens is, by and large, mediated through intercellular and/or intracellular receptor mediated
- 15 activation via ligand binding. Typically, ligands which interact with receptors to bring about a suitable biochemical/metabolic response are known as agonists and those that prevent, or hinder, a biochemical/metabolic response are known as antagonists.

- 20 The interaction of T helper cells and B-cells involves receptor/ligand binding. The B-cell CD40 receptor (CD40 is a monoclonal antibody which recognises the receptor) and the T-cell ligand gp39, referred to hereinafter as CD154 (CD 154 is a monoclonal antibody which recognises gp39) interact and play a pivotal role in both
- 25 the humoral and cellular immune responses to T- cell dependent (TD antigens). In the absence of either molecule there is no isotype switching in response to a T cell dependent antigen, no germinal centre formation, and no enhanced secondary antibody responses (1,2)

- 30 The human CD40 receptor is a 48kDa, 277 amino acid polypeptide, transmembrane glycoprotein expressed predominantly at the B- cell surface. This receptor is also expressed by a number of other cell types. For example and not by way of limitation,

monocytes, basophils, eosinophils, endothelial cells, Langerhans cells, keratinocytes, Kaposi's sarcoma cells.

5 The human CD154 is a 33kDa, 261 amino acid polypeptide, transmembrane glycoprotein predominantly expressed at the T cell surface. This ligand is also expressed by a number of other cell types. For example, and not by way of limitation, mast cells, basophils, eosinophils, dendritic cells and monocytes. It is of note that CD154 has not been shown to be expressed in somatic cells other than those which are closely associated with the immune system.

10

Given the importance of the interaction of CD40 receptor with CD154 we have undertaken a study of the interaction between these molecules by expressing CD154 in cells which do not naturally express CD154, namely mouse fibroblasts expressing a mismatched MHC class, and used these cells as an immunogen. We anticipated that
15 this would act as a potent stimulator of the immune system.

It is known that blocking the interaction of CD40 with CD154 can suppress the immune response. For example, the use of anti- CD154 antibodies is known to abrogate the interaction between CD40 receptor and CD154 and result in attenuation
20 of the immune system in response to allografts (WO9856417 & WO9858669); suppression of autoimmune disease (WO9900143) and blood clotting disorders (WO9858672). We predicted that the recombinant expression of CD154 in MHC mismatched cells would promote an immune response to said cells. To our surprise, these cells did not promote an immune response but resulted in immune suppression
25 toward the injected transfected fibroblasts.

It is apparent that this observation has important implications with respect to allotypic recognition of implanted cells/tissues/organs. The expression of CD154 in cell types which do not naturally express this ligand resulted in failure of the immune
30 system to recognise the implanted cells as foreign. This has important implications with respect to tissue/organ transplantation and tissue/organ rejection by the host receiving the transplanted tissue/organ.

According to a first aspect of the invention there is provided at least one cell/tissue/organ for use in tissue engineering and/or organ transplantation wherein said cell/tissue/organ does not naturally express the CD154 ligand but is adapted to
5 express at least an effective part of the CD154 ligand.

Reference herein to a part of CD154 includes reference to at least part of the extracellular domain.

10 In a preferred embodiment of the invention said cell/tissue/organ is transfected with DNA encoding at least the effective part of CD154, or a homologue thereof.

In yet a further preferred embodiment of the invention said DNA is genomic DNA.

15 In yet still a further preferred embodiment of the invention said DNA is cDNA.

In yet a still further preferred embodiment of the invention said cells/tissues/organ are of mammalian origin. Ideally said cells/tissues/organs are of human origin.

20 In yet still a further preferred embodiment of the invention said cells/tissues are selected from the following cell types: fibroblast; keratinocyte; osteoblast; chondrocyte; neurones, myocytes; hepatocytes; splenocytes, pancreatic β cells.

According to a second aspect of the invention there is provided a vector for use in the
25 transfection of a selected cell/tissue/organ type for use in tissue engineering and/or organ transplantation characterised in that it contains a DNA molecule encoding at least an effective part of CD154 ligand, or a homologue thereof.

In a preferred embodiment of the invention said vector is adapted for the
30 recombinant expression of CD154 ligand.

Conventionally, nucleic acid molecules used to transfect cells are referred to as vectors. Vectors used in genetic engineering are typically circular molecules, (although some may be linearised prior to transfection to facilitate the introduction of DNA into a host cell). Vectors of this type are referred to as plasmids, phages, or phagemids. In many examples these vectors have been genetically engineered to adapt them for expression in eukaryotic cells. For example, and not by way of limitation the provision of cell/tissue specific promoter elements which facilitate expression in a specific cell/tissue type; the provision of viral promoters which provide high levels of constitutive expression.

10

In addition to the above identified vectors, viral based vectors are used in transfection and in particular, gene therapy, to deliver genes to tissues *in vivo*. These vectors typically retain the capability to infect a host cell but are genetically modified to render the virus biologically disabled; this latter feature facilitates its removal from the organism and prevents its uncontrolled spread through host tissues. Examples of viral based vectors used in gene therapy include by example and not by way of limitation: adenovirus; retrovirus; parvovirus; and herpesvirus

In a further preferred embodiment of the invention said adaptation comprises the inclusion of appropriate expression control sequences which optimise the expression of the vector encoded nucleic acid molecule.

It will be apparent to one skilled in the art that said adaptation relates to a vector adapted for expression in a eukaryotic cell. For example, and not by way of limitation, said adaptation comprises the provision of constitutive, inducible, or repressible promoter elements; and/or the provision of polyadenylation control sequences for optimal expression; and/or the provision of selectable markers to allow the selection of said vector in a eukaryotic cell.

Furthermore the provision of regulatable promoter elements to control the amount of CD154 available to the cell/tissue is advantageous. It is desirable to regulate the amount of CD154 in accordance with the immune status of the host. For example,

once the cell/tissue/organ has been implanted it is may be beneficial to reduce the amount of CD154 expressed as the host becomes tolerant of the transplanted cell/tissue/organ. Alternatively, CD154 expression can be increased if the host begins to reject the donated cells/tissue/organ. This can be facilitated by modulation of the regulatable promoter to increase or decrease the amount of CD154.

In yet a further preferred embodiment of the invention there is provided a vector comprising a cell/tissue specific promoter sequence for use in the cell/tissue specific expression of CD154 according to any previous aspect or embodiment of the invention.

In a preferred embodiment of the invention said cell/tissue/organ is selected from the following tissue types: neuronal, muscle (e.g. smooth, striated, cardiac), bone, cartilage, liver, kidney, respiratory epithelium, endothelium, haematopoietic cells, spleen, pancreas, skin, stomach, intestine, oesophagus; blood vessels.

According to a third aspect of the invention there is provided a method to transfect a selected cell/tissue comprising:

- i. providing a vector according to the invention and adding said vector to cells/tissues;
- ii. incubating cells/tissues under conditions conducive to the introduction and maintenance of a vector;
- iii. exposing said cells to an agent at a concentration sufficient such that at least those cells/tissues including said vector are selected for; and optionally,
- iv. culturing said cells/tissues containing said nucleic acid molecule and, optionally, further still,
- v. storing said cell culture prior to use.

In a preferred method of the invention said cell/tissue is a mammalian cell/tissue. Ideally said mammalian cell/tissue is of human origin.

In a further preferred method of the invention, said transfection is transient. In the event that a transient transfection is required; steps (ii) and (iii) are not necessary.

- 5 It will be apparent to a man skilled in the art that where steps (ii) and (iii) are undertaken stable transfection is facilitated

Eukaryotic cells may be transfected via a variety of techniques. For example, and not by way of limitation, DNA may be introduced into mammalian cells via calcium phosphate precipitation (Graham, FL and Van der Eb AJ, (1973) Virology 52, p456).
10 This technique is particularly useful for both transient and stable transfection. An alternative to calcium phosphate precipitation is DEAE dextran mediated transfection (Gluzman, Y. (1981) Cell, 23, 175). This method is used primarily for transient transfection rather than stable transfection.

15

More recently, eukaryotic cells have been transfected using a pulse of high voltage electricity which, when passed through a culture of cells in the presence of vector DNA, momentarily results in permeabilisation of the cell membrane thus facilitating the introduction of vectors into said cells. This procedure is referred to as
20 electroporation. Furthermore, an alternative to the above mentioned methods is so called "ballistic" transfection where DNA coated microbeads are "shot" into cells/tissues to deposit the DNA into the cell/tissue.

According to a fourth aspect of the invention there is provided a therapeutic
25 composition comprising at least one cell/tissue according to any previous aspect or embodiment of the invention.

Preferably, said therapeutic composition is adapted for use in tissue engineering. More preferably still, said tissue engineering is the replacement of diseased or
30 damaged tissue.

Conditions which would benefit from therapeutic tissue engineering include by example, and not by way of limitation, arthritis and the replacement of joints; skin grafting for burn victims or injuries resulting in sever contusions; replacement of coronary arteries; replacement of diseased or damaged nerves and/or muscles;

5 replacement of pancreatic β cells.

According to a fifth aspect of the invention there is provided at least one organ wherein said organ for use in organ transplantation comprises at least one cell/tissue according to any previous aspect or embodiment of the invention.

10

In a preferred embodiment of the invention said organ comprises at least one cell/tissue transfected with the vector according to any previous aspect or embodiment of the invention.

15 According to a sixth aspect of the invention there is provided a cell/tissue composition for use in cosmetic tissue engineering comprising at least one cell/tissue according to any previous aspect or embodiment of the invention.

In a preferred embodiment of the invention said cell/tissue comprises at least one

20 cell/tissue transfected with the vector according to any previous aspect or embodiment of the invention.

According to an seventh aspect of the invention there is provided a method of treatment comprising;

25

- i) providing at least one cell/tissue which does not normally express CD154, or effective part thereof, and adapted so that same expresses at least the effective part of CD154;
- ii) administering said cells/tissues to a patient to be treated; and optionally,
- 30 iii) monitoring the status of said cells/tissues by the patient.

According to an eighth aspect of the invention there is provided a method of treatment comprising;

- iv) providing at least one organ which does not normally express CD154, or
5 effective part thereof, comprising at least one cell/tissue expressing at least the effective part of CD154;
- v) surgical implantation of said organ to a patient to be treated; and optionally
- vi) monitoring the status of said cells/tissues by the patient.

- 10 When said cell/tissue/organ comprises an inducible promoter whereby CD154 may be selectively expressed said method may further involve monitoring/regulating the administration of at least one agent that activates said promoter.

- 15 In a preferred method of the invention said cell/tissue/organ comprises at least one cell transfected with a nucleic acid molecule encoding at least the effective part of CD154 according to any previous aspect or embodiment.

According to a further aspect of the invention there is provided a vehicle wherein said vehicle has least one cell according to the invention attached thereto.

20

Vehicle is defined as any structure to which cells according to the invention may attach and proliferate. For example and not by way of limitation, a prosthesis, implant, matrix, stent, gauze, bandage, plaster, biodegradable matrix and polymeric film.

25

In a preferred embodiment of the invention there is provided a therapeutic vehicle comprising cells according to the invention wherein said therapeutic vehicle is adapted to be applied and/or implanted into a patient requiring therapeutic tissue engineering.

30

In yet a further preferred embodiment of the invention there is provided a therapeutic vehicle comprising a matrix material (for example, and not by way of limitation, a

matrix material which is synthetic or naturally occurring and either long-lasting or biodegradable) comprising at least one cell according to the invention for use in surgical implantation procedures.

- 5 According to a yet further aspect of the invention there is provided a cosmetic vehicle comprising at least one cell according to the invention for use in cosmetic tissue engineering.

10 An embodiment of the invention will now be described, by example only, and with reference to the following Figures;

Figure 1 is a representation of groups of five BALB/c mice immunised twice intraperitoneally with 5×10^4 L cells (closed circles), CD154 L cells (open squares), or PBS (closed triangles);

15

Figure 2 represents groups of five BALB/c mice immunised with L cells or CD154 L cells and boosted with either L cells or CD154 L cells;

20

Figure 3 represents groups of five BALB/c mice immunised with CD154 L cells or PBS, immunised again with normal L cells 3 and 6 weeks later and bled 8 days after the last immunisation; and

25

Figure 4 represents measurements of serum nitrate levels of mice after immunisation with L cells or CD154 L cells.

MATERIALS AND METHODS

Cells and antibodies

30

L929 cells (L cells) and CD154 transfected L929 cells (CD154 L cells) were kindly provided by DNAX Research Institute, California. CD154 transfected L929 cells

were prepared as described elsewhere [15]. Anti-CD40 antibody 1C10 (9) was purified on a protein G column from hybridoma supernatant produced in a bioreactor by Sheffield hybridomas, Sheffield. The MR1 anti-CD154 mAb was purchased from Pharmingen.

5

Mice and Immunisations

BALB/c female mice of 8-12 weeks of age were obtained from the University of Sheffield Field Laboratories. L929 cells were removed from tissue culture flasks using EDTA (0.5mM), washed in PBS and 5×10^4 cells injected intraperitoneally into MHC mismatched BALB/c mice. Mice were bled 10 days post-primary immunisation and seven days after each subsequent immunisation.

10

Measurement of antibody responses

15

Antibody responses to L929 cell surface antigens were determined by Flow cytometric analysis. L929 cells, at 10^6 cells/ml, were incubated in FACS buffer (PBS, 3% BSA, 0.01% Sodium azide) at 4°C for 20 minutes with serial dilutions of mouse antisera for 20 minutes. Cells were then washed three times with FACS buffer and incubated with a FITC labelled goat anti-mouse immunoglobulins (Pharmingen) for 20 minutes at 1:100, washed three times and analysed using a Becton Dickinson FACScan analyser and "FacsanTM" and "LysisTM" software. Dead cells were gated out by forward and 90° angle light scatter. Mean fluorescence intensities (MFI) were plotted against dilution and examples of such plots are shown in figure 1. To simplify the remaining figures mean endpoint titres are shown, and were determined by the points of intersection of the MFI curves with those of normal mouse serum (i.e the PBS group from figure 1). Statistical analyses were by Student's t test.

20

25

Assay for Nitrate as a measure of Nitric oxide production

30

Sera were assayed for Nitrite levels (as an indicator of Nitric oxide production) 2h post injection with L cells or CD154 L cells by the addition of 50µl test serum to 100µl Greiss reagent (0.5% Sulfanilamide (w/v) 0.05 % Naphthylethylene (w/v) , 1.125% phosphoric acid). Sodium nitrite standards were double diluted across the plate starting at 100mM. The plates were incubated at RT for 10min and absorbance at 540nm measured.

RESULTS

Expression of CD154 on antigenic cells inhibits the alloantibody response

The antibody responses of BALB/c mice against normal or CD154 expressing L929 cells were not detectable by this flow cytometric assay following a single immunisation. However two i.p injections of L cells gave rise to antibody responses against L cells of around 1/1000 (Figure 1). In contrast mice immunised with CD154 L cells produced no detectable response against L cells even after two immunisations (Figure 1). We considered it possible that these apparent differences in immunogenicity were caused by antigenic variation between the two cell lines as responses were assayed against normal L cells; however similar results were seen when CD154 L cells were used as the antigen in the assay, Figure. Thus the results were due to a lack of response to the CD154 L cells in immunised mice.

25

CD154 L cells fail to prime for an alloantibody response against normal L cells, but do not induce tolerance.

Mice immunised first with CD154 L cells, and then with normal L cells failed to produce a normal secondary antibody response against the L cells, thus CD154 expression inhibited priming of the antibody response against L cells ($p=0.013$; Fig

2). It was possible that the CD154 L cells were inducing tolerance, leading to a lack of response on secondary exposure to normal L cells. To determine whether this was the case, two groups of mice were immunised with two doses of L cells, but one of the groups had previously been immunised with CD154 L cells. Had the CD154
5 expressing cells induced tolerance then the latter group should have produced a lower immune response. In fact this was not the case, and responses between the two groups were the same ($p=0.23$; Fig 3). Thus it would appear that CD154 expression does not result in tolerance, but rather a lack of recognition of the antigen on initial exposure.

10 **Induction of Nitric oxide by CD154 expressing L929 cells**

As CD40 ligation had been shown to enhance production of NO by macrophages [7] and NO production is responsible for a generalised immunosuppression seen in acute bacterial infection [8], we investigated whether NO levels were increased in mice
15 immunised with CD154 L cells. As shown in figure 4a, there was an increase in serum nitrate, indicating a rise in NO levels *in vivo* following immunisation with CD154 expressing cells which was greater than that seen after immunisation with normal L929 cells. It does not appear however that NO is responsible for the suppression of immune responses against CD154 L cells, as co-injection with the NO
20 synthase inhibitor, L-NAME abrogated the nitric oxide production but had no effect on suppression (Fig 4b)

The suppressive effect of CD154 expression is probably not related to the particulate form of the antigen

25

We have shown strong positive effects of CD40 ligation on immune responses to soluble antigens using anti-CD40 antibodies (6). However when the agonistic anti-mouse CD40 antibody 1C10 [9] (500 μ g) was co-injected with normal L929 cells, the antibody response was neither suppressed nor significantly enhanced ($p=0.33$; fig 4b).
30 The suppression mediated by CD154 expression is therefore unlikely to be related simply to the form of the antigen, administered as whole cells rather than soluble protein

Reversal of inhibition with anti-CD154

The inhibition of alloantibody responses by CD154 expression is clearly reversed by
5 pre-incubation of the cells with 10µg/ml MR1 (anti-CD154, 10) antibody (p=0.0013),
again indicating the suppression of responses by these cells is due to CD154
expression and not antigenic or other differences between these cells and normal L
cells (Figure 4b).

10 **DISCUSSION**

Interactions between CD154 and CD40 play a very important role in immune
responses. In general, stimulation of B cells through CD40 induces strong B cell
activation, proliferation and isotype switching especially in co-operation with
15 signalling by other factors such as antigen (or anti-IgM), and cytokines such as IL4.
Signalling through CD40 also appears to be important in initiating and maintaining
germinal centres [1]. Activation of B cells through anti-CD40 antibodies in vivo can
also give rise to enhanced isotype switching, greatly increased antibody responses
[6,11] and B cell proliferation [Dullforce, Greenwood and Heath, in preparation]. As
20 we had demonstrated strong adjuvant-like effects of CD40 ligation on antibody
responses in vivo, we considered that cell-surface expression of the CD40 ligand,
CD154, may be a potent means of enhancing anti-cellular immune responses. An
analogous approach had been used successfully utilising CD80 and CD86 transfection
to enhance the CTL response against tumour cells in vivo [12]. We therefore
25 examined the effect of transfection with CD154 on the alloantibody response to
murine L929 cells.

BALB/c mice (H-2^d) were immunised with the MHC mismatched cell line L929,
untransfected or stably transfected and expressing murine CD154 on the membrane.
30 Contrary to our expectations we found that expression of CD154, rather than
enhancing the alloantibody response to the L929 cells, actually suppressed the
response. This suppression only became evident after two immunisations because of

the poor primary response to normal L cells. However, the suppressive effect was mediated at the primary immunisation as the response to a second injection with normal L cells was suppressed by primary immunisation with CD154 L cells. The lack of responsiveness to CD154 L cells was not caused by antigenic differences
5 between the two cell lines, as similar results were obtained when CD154 L cells were used as antigen to detect the antibody. It appeared possible that the CD154 expression was rendering the L cells tolerogenic. However, that did not appear to be the case as mice immunised with CD154 L cells, followed by two doses of L cells, responded normally to the second dose of L cells. It appears, therefore, as though the expression
10 of CD154 by L cells simply prevents or suppresses effective priming or activation of the allospecific cells rather than induces tolerance.

Earlier experiments on the in vivo effects of CD40 ligation have been performed using soluble antigens and soluble anti-CD40 antibody []. It was therefore important
15 to determine whether the form of the antigen was the important factor in this apparent reversal of the effects of CD40 ligation. To this end mice were immunised with L cells and an agonistic anti-mouse CD40 antibody, 1C10 [] In this case the antibody response to the L cells was enhanced. Thus it would appear that the suppressive effect of CD154 expression on the L cells is dependent on: the extent of CD40 cross-
20 linking; the temporal differences between that cross linking by a cell surface antigen and that of soluble antibody; or qualitative differences between antibody and ligand induced CD40 signalling.

Of course immune responses to allogeneic cells are different in many ways to
25 immune responses against soluble antigens, not least in that the antigen itself is probably directly recognised by T cells without processing by a specialised APC. From the perspective of the B cell, encounter with a CD154 expressing L cell must be similar to an encounter with an activated T cell which may well also be expressing antigens which do not appear during B cell maturation, thus not allowing elimination
30 of B cells reactive with these antigens in the bone marrow. One of these would be the T cell receptor idiotype, and another may well be CD154. It has been proposed that autoimmune responses against newly expressed antigens (such as hormones and

breast milk) do not normally occur because of the lack of a "danger" signal. There is little evidence for CD154 expression in the bone marrow microenvironment, thus B cells expressing surface immunoglobulin specific for CD154 as well as TCR idiotopes might be expected to be present in the periphery. Because of the function of CD154, a CD154 specific B cell coming across it for the first time would receive a potent "danger" signal in the form of CD40 ligation. Thus it might be expected that strong autoantibody responses against CD154 would be produced. This is clearly not the case, and we propose that simultaneous and long-lived stimulation through surface immunoglobulin and CD40 and/or extensive cross-linking of the two receptors, may anergise the B cell preventing the production of large amounts of autoantibody against CD154 and possibly TCR idiotopes.

We consider that transfection of donor cells for transplantation with CD154 will have some role to play in enhancing the acceptance of allografts by the recipient.

REFERENCES

- 1) Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T and Kikutani, H. . Immunity 1, 167 1994
- 2) Xu J.C., Foy T.M., Laman J.D., Dunn J.J., Waldshmidt T.J., Elsemore J., Noelle R.J. and Flavell R.A. Immunity 1 423, 1994
- 3) Yang, Y and Wilson, J.M. Science 273, 1862, 1996
- 4) Van Essen, D., Kikutani, H and Gray, D. Nature 378, 620, 1995
- 5) Armitage, R.J., Fanslow, W.C., Strockbine, L., Sato, T.A., Clifford, K.N., Macduff, B.M., Anderson, D.M., Gimpel, S.D., Davis-Smith, T., Maliszewski, C.R., Clark, E.A., Smith, C.A., Grabstein, K.H., Cosman, D and Spriggs, M.K. Nature 357, 80, 1992
- 6) Dullforce, P., Sutton, D and Heath, A.W. Nature Medicine 4, 88, 1998

- 7) Tian, L.C., Noelle, R.J. and Lawrence, D.A. Eur. J. Immunol. 25:306, 1995
- 8) Alramadi, B.K., Meissler, J.J., Huang, D. and Eisenstein, T.K EurJ.Immunol 22 , 2249, 1992
- 5 9) Heath, A.W., Wu, W.W. and Howard, M Eur J.Immunol. . 24, 1828, 1994
- 10 10) Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA and Aruffo A. P.N.A.S (USA) 89 , 6550, 1992
- 11 11) Ferlin, W.G., Severinson, E., Strom, L., Heath, A.W., Coffman, R.L. and Howard, M. Eur. J. Immunol. 26, 2911, 1996
- 12 12) Ramarathinam, L., Castle, M., Wu, Y. and Liu, J. J.Exp.Med. 179: 1205, 1994
- 15 13) Kaye, J and Janeway CA. J.Exp.Med. 159, 1397, 1984
- 14 14) Miyashita, T., McIlraith, M.J., Grammer, A.C., Miura, Y., Attrep, J.F., Shimaoka, Y and Lipsky, P.E. J.Immunol. 158 ,4620, 1997
- 20 15) Randall, T.D., Heath, A.W., Santos-Argumedo, L., Howard, M.C., Weismann, I.L. and Lund, F.E.. Immunity . 8, 733, 1998
- 25

AMENDED CLAIMS

1. Use of a cell, which does not naturally express CD154, wherein said cell is transfected with DNA encoding CD154, for the manufacture of a tissue composition for use in tissue engineering.
2. Use according to Claim 1 wherein said cell is transfected with genomic DNA.
3. Use according to Claim 1 wherein said cell is transfected with cDNA.
4. Use according to any of claims 1 - 3 wherein said cell is of mammalian origin.
5. Use according to claim 4 wherein said cell is of human origin.
6. Use according to any of claims 1 - 5 wherein said cell is selected from the following cell types: fibroblast; keratinocyte; osteoblast; chondrocyte; neurone; myocyte; hepatocyte; splenocyte; pancreatic β cells.
7. Use of a cell according to any of claims 1-6 for use in the manufacture of a medicament for use in therapeutic tissue engineering.
8. Use of a cell according to any of claims 1-6 for use in the manufacture of a medicament for use in cosmetic tissue engineering.
9. Use of a vector which includes a nucleic acid molecule which encodes CD154, wherein said vector is adapted for recombinant expression of CD154, for the manufacture of a medicament for use in tissue engineering.
10. Use of a vector according to claim 9 wherein said vector comprises a cell/tissue specific promoter sequence.
11. Use of a vector according to claim 10 wherein said promoter is cell/tissue specific for one of the following tissue types: neuronal; smooth muscle; striated

muscle; cardiac muscle; bone; cartilage; liver; kidney; respiratory epithelium; endothelium; haematopoietic cells; spleen; pancreas; skin; stomach; intestine; oesophagus; blood vessels.

12. An *in vitro* method to transfect a selected cell/tissue wherein said cell/tissue does not naturally express CD154, comprising;

- i) incubating cells/tissues under conditions conducive to the introduction and maintenance of a vector according to any of claims 9-11;
- ii) exposing said cells to an agent at a concentration sufficient such that at least those cells/tissues including said vector are selected for and optionally,
- iii) culturing said cells/tissues containing vector; and, optionally further still,
- iv) storing said cell culture prior to use.

13. A method according to claim 12 wherein said cell/tissue is a mammalian cell/tissue.

14. A method according to claim 12 or 13 wherein said mammalian cell/tissue is of human origin.

15. A method according to any of claims 12-14 wherein said transfection is transient.

16. An organ comprising at least one cell, wherein said cell does not naturally express CD154, which cell has been transfected with a vector according to any of Claims 9-11.

17. A method of treatment comprising:

- i. providing at least one cell wherein said cell does not naturally express CD154, which cell is transfected with a nucleic acid molecule encoding CD154; and
- ii. administering said cell to a patient to be treated.

18. A therapeutic vehicle comprising a cell according to any of claims 1-8.
19. A therapeutic vehicle according to claim 18 wherein said therapeutic vehicle is selected from: a prosthesis; implant; matrix; stent; gauze; bandage; plaster; biodegradable matrix; polymeric film.
20. A cosmetic vehicle comprising a cell according to any of claims 1-8.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07605 A1(51) International Patent Classification⁷: C12N 15/12,
C07K 14/705, C12N 5/10, A61K 35/12, 7/00, A61L 15/00(74) Agent: HARRISON GODDARD FOOTE; Tower
House, Merrion Way, Leeds LS2 8PA (GB).

(21) International Application Number: PCT/GB00/02652

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 10 July 2000 (10.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9917180.3 23 July 1999 (23.07.1999) GB(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). ..(71) Applicant (*for all designated States except US*): UNIVERSITY OF SHEFFIELD [GB/GB]; Western Bank, Sheffield S10 2TN (GB).

Published:

— With international search report.

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): HEATH, Andrew, William [GB/GB]; University of Sheffield, Medical School, Sheffield S10 2RX (GB).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CD154 LIGAND, AND RECOMBINANT CELLS EXPRESSING IT

(57) Abstract: The invention relates to cells and/or tissues and/or organs which do not naturally express the cell surface receptor CD40 ligand, CD154, for use in therapeutic and cosmetic tissue engineering and/or organ transplantation.

WO 01/07605 A1

Figure 1





Figure 2




Figure 3






Figure 4



#4.

Attorney Docket No. H0664/7003

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

IMMUNOSUPPRESSION BY CELL SURFACE EXPRESSION OF RECOMBINANT CD154

the specification of which is attached hereto unless the following is checked:

☒ [X] was filed on January 23, 2002, as United States Application No. 10/031,774, bearing attorney docket no. H0664/7003, and was amended on January 23, 2002, which is a 35 U.S.C 371 National Stage of PCT/GB00/02652, filed July 10, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or section 365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign PCT International Application(s) and any priority claims under 35 U.S.C. §§119 and 365(a),(b):

			Priority Claimed	
<u>9917180.3</u>	<u>Great Britain</u>	<u>July 23, 1999</u>	<input checked="" type="checkbox"/> [X]	<input type="checkbox"/> []
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	YES	NO
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> []	<input type="checkbox"/> []
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	YES	NO
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> []	<input type="checkbox"/> []
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	YES	NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u> </u>	<u> </u>
(Application Number)	(filing date)
<u> </u>	<u> </u>
(Application Number)	(filing date)

Serial No.: 10/031,774

Page 2

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)	(filing date)	(status-patented, pending, abandoned)
(Application No.)	(filing date)	(status-patented, pending, abandoned)

PCT International Applications designating the United States:

(PCT Appl. No.)	(U.S. Ser. No.)	(PCT filing date)	(status-patented, pending, abandoned)
-----------------	-----------------	-------------------	---------------------------------------

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Robert M. Abrahamsen	40,886	Jason M. Honeyman	31,624	Randy J. Pritzker	35,986
Konstantinos Andrikopoulos	48,915	Robert E. Hunt	39,231	Edward J. Russavage	43,069
John N. Anastasi	37,765	Peter C. Lando	34,654	Robert A. Skrivaneck, Jr.	41,316
Ilan Barzilay	46,540	M. Brad Lawrence	47,210	Alan W. Steele	45,128
Carole Boelitz	48,958	Helen C. Lockhart	39,248	Mark Steinberg	40,829
Gary S. Engelson	35,128	Matthew B. Lowrie	38,228	Joseph Teja, Jr.	45,157
Neil P. Ferraro	39,188	William R. McClellan	29,409	Maria A. Trevisan	48,207
Thomas G. Field III	45,596	Daniel P. McLoughlin	46,066	John R. Van Amsterdam	40,212
Stephen R. Finch	42,534	Chantal Morgan-D'Apuzzo	48,825	Robert H. Walat	46,324
Edward R. Gates	31,616	James H. Morris	34,681	Kristin D. Wheeler	43,583
Richard F. Giunta	36,149	Timothy J. Oyer	36,628	Lisa E. Winsor	44,405
Lawrence M. Green	29,384	Edward F. Perlman	28,105	David Wolf	17,528
George L. Greenfield	17,756	Elizabeth R. Plumer	36,637	Douglas R. Wolf	36,971
James M. Hanifin, Jr.	39,213	Michael J. Pomianek	46,190		
Steven J. Henry	27,900	Jeffrey B. Powers	45,021		

23628

CUSTOMER NUMBER:

Address all telephone calls to John R. Van Amsterdam at telephone no. (617) 720-3500. Address all correspondence to:

John R. Van Amsterdam
c/o Wolf, Greenfield & Sacks, P.C.,
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

21. AUG. 2002 16:50

HARRISON GODDARD

10031774 NO. 707 P. 5

Serial No.: 10/031,774

Page 3

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



19th Aug. 2002
Date

Inventor's signature

Full name of first/sole inventor:

Andrew W. Heath

Citizenship:

Great Britain

Residence:

Sheffield, Great Britain G.B.N.

Post Office Address:

University of Sheffield, Medical School, Beech Hill Road, Sheffield
S10 2RX, Great Britain